Mutations in cancers other than HCC associated with a negative outcome for ICI treatment include inactivating mutations in JAK1/2 [23] or beta-2-microglobulin in melanoma [24], MDM4 amplifications, or EGFR alterations in different stage IV tumors [25] or STK11/LKB1 alterations in KRAS-mutant lung adenocarcinoma [26]. This evidence concerns the gene B2M and lung adenocarcinoma.